Healthcare

PYC presented safety, tolerability and exploratory efficacy data from the single ascending dose study of PYC-003 in healthy volunteers and in participants with polycystic kidney disease, at nephrology conferences in Australia and New Zealand and in the United States. In the Phelan-McDermid syndrome program, …

Racura said its first patient was safely treated with RC220 in combination with osimertinib in the HARNESS-1 trial for EGFR-mutated non-small cell lung cancer, with positive initial safety data. The Phase 1 CPACS trial expanded to South Korea, and ethics approval was received for …

Regis reported revenue from services of A$1,350.6 million, up 16% on the prior corresponding period, and underlying EBITDA of A$138.0 million, up 9.7%. The underlying EBITDA margin declined to 10.2% from 10.8%, with staff expenses at 78.1% of revenue from services, up 1.5 percentage …

Ramsay said ASIC had registered the Demerger Booklet for the proposed distribution to Ramsay shareholders of its 52.79% shareholding in Ramsay Générale de Santé SA. The company referred back to an ASX announcement of 16 October 2026.Shareholdermeetings were set for 24 November 2026, immediately …

ResMed's Form 10-Q reported net revenue of US$1.41 billion against US$1.34 billion, andNet Incomeof US$418.4 million against US$348.5 million. Diluted EPS was US$2.92 against US$2.37, on 143.4 million diluted shares against 146.9 million a year earlier. Sleep and Breathing Health product revenue rose to …

Sonic reported revenue of A$10,867 million for the year to 30 June 2026, up 13%, and underlying EBITDA of A$1,933 million, up 11%. Statutory EBITDA was A$1,882 million, and underlying net profit was A$621 million, up 17%, with statutory net profit of A$608 million. …

Summerset recorded 415 occupation right sales for the quarter ending 30 September 2026, made up of 175 new sales and 240 resales. Q3 resales rose 36% on the prior corresponding quarter and were ahead of the 227 resales in Q2 2026. Year-to-date sales were …